Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine

Delavirdine (DLV), a non-nucleoside reverse transcriptase inhibitor (RTI) of human immunodeficiency virus type 1 (HIV-1), was evaluated in two and three-drug combinations against acute and co-culture infections of HIV-1 JRCSF in human peripheral blood mononuclear cells. DLV combined with didanosine...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antiviral research 1997-03, Vol.34 (1), p.51-63
Hauptverfasser:	Chong, Kong-Teck, Pagano, Paul J
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-HIV Agents - administration & dosage Anti-HIV Agents - pharmacology Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Cell Line Delavirdine Didanosine - administration & dosage Didanosine - pharmacology DNA, Viral Drug Combination HIV-1 HIV-1 - drug effects HIV-1 - isolation & purification human immunodeficiency virus 1 Humans Indoles - administration & dosage Indoles - pharmacology Medical sciences Pharmacology. Drug treatments Piperazines - administration & dosage Piperazines - pharmacology Polymerase Chain Reaction Reverse transcriptase inhibitors Reverse Transcriptase Inhibitors - administration & dosage Reverse Transcriptase Inhibitors - pharmacology Zidovudine - administration & dosage Zidovudine - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!